Compare Nebius Group NV (NBIS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs Vertex Pharmaceuticals Incorporated — how do they compare? Nebius Group NV trades at $219.96 (market cap $46.37B), while Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.6× Nebius Group NV's market cap. Which is the better fit depends on your goals.
| NBIS | VRTX | |
|---|---|---|
Market Cap | $46.37B | $121.95B |
Sector | Technology | Health |
52-Week High | $286.69 | $529.59 |
52-Week Low | $50.40 | $366.54 |
Enterprise Value | $46.56B | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NBIS trades at $182.62, up 2.76% today, with a bearish technical signal despite oversold RSI readings. The company reported a net income of $82.50M in 2025, with revenue of $529.80M, and shows strong projected profit margin expansion to 93.08% in 2026. Recent news highlights a significant stake increase by Nvidia, fueling positive sentiment.
Outlook is mixed: strong analyst support (88.89% buy ratings) and a $260.67 price target suggest upside, but high valuation ratios (P/E 70.51) and negative cash flow from investing pose risks. Investor focus is on execution of AI-driven growth amid competitive pressures.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
